Can ketamine infusions help with ADHD
Ketamine as an antidepressant
|Non-proprietary name||Ketamine, esketamine|
|effect||high (at> 40% with MD)|
|indication||Therapy of (comorbid) major depression|
Ketamine is a drug that is usually used in human and veterinary medicine for anesthesia and analgesia (for example in emergency medicine or during operations). In addition, ketamine is also used as an intoxicant (known there as Special K, Kate or Vitamin K known) used.
Recent studies, including from Charité Berlin, show that low-dose ketamine when administered intravenously can sometimes be noteworthy, even in the long termantidepressant effects in therapy-resistant depression, especially major depression, may have. Significant antidepressant effects were also found in post-traumatic stress disorder. In more than 40% of severely depressed patients, ketamine shows antidepressant effects.
Depression is a particularly common secondary disorder in up to 40% of ADHD sufferers and has significant negative effects on ADHD symptoms, which is why the therapy of depression is often the focus of multimodal ADHD treatment. Especially in the case of acute suicidality, ketamine can be a quick and effective alternative treatment to the drugs available to date.
Mechanism of action
The glutamate-NMDA receptor complex is known for ketamine as a site of action. As an important neurotransmitter of the central nervous system, glutamic acid causes an influx of calcium, which is responsible for numerous intracellular processes. By preventing the NMDA receptor-dependent acetylcholine release, ketamine influences the cholinergic system, also inhibits other glutamate receptors, has a weak agonistic effect on opioid receptors and modulates and activates certain receptors on the GABAA receptor.
In addition, ketamine acts as a peripheral reuptake inhibitor of norepinephrine and dopamine at the synaptic endplate, accompanied by intensification of endogenous and exogenous catecholamine effects.
Using Ketamine for Depression
In some studies, ketamine has been shown to have clear and rapid antidepressant effects. Since conventional, antidepressant drugs take a few weeks to take effect, ketamine could play an important role in the future, especially in the treatment of patients who are acutely suicidal.
Due to the high number of patients who do not react or react insufficiently to the commonly prescribed groups of antidepressants (non-responders), ketamine could also play an important role in the accompanying treatment of therapy-resistant major depression.
First results on effectiveness in depression
The antidepressant effect of ketami has only been studied for a few years. However, initial investigations have produced surprising results with regard to the antidepressant effect of differently applied ketamine in patients also with therapy-refractory, persistent depression and with bipolar disorder.
For example, a study from 2013 reports that after sublingual administration of low ketamine doses (weekly administration of 10 mg), 77% of the participants experienced significant, constant improvements in mood and improved sleep.
A 2014 study with 21 patients with bipolar disorder was also able to demonstrate effects of ketamine in brain regions within the framework of imaging procedures, which are of particular importance in depression. The symptom improvements were significantly correlated with changes in the right ventral striatum.
Carlos Zarate (NIMH) examined the effects of intravenously administered ketamine in 18 severely depressed patients in 2006, with 71% of the patients responding positively within 40 minutes to a few hours. On the first day, the depressive symptoms were already reduced by 50%. After the second dose on the next day, no more depressive symptoms could be detected in around 30% of the patients, and in a further third the symptoms returned after a week.
Numerous other, mainly US studies, have also shown significant positive effects in ketamine treatment for depression.
Antidepressant Mechanisms of Action
It is considered likely that the AMPA receptor-mediated glutamatergic system is weakened in patients with depression. This is relevant for synaptic plasticity in numerous areas of the brain, including in particular the hippocampus and the cerebellum. The AMPA system seems to be faster and more direct to release the growth factor BDNF (Brain-derived neurotrophic factor) than a cascade involving SSRi and tricyclic antidepressants. In addition, BDNF is a marker for the success of the therapy: the patients respond better to the therapy, the more the BDNF levels rise.
In depressed patients, stressors seem to suppress the AMPA system; Ketamine, however, releases the AMPA blockade by blocking the NMDA receptor.
Very common side effects described are psychotropic effects (pseudohallucinations, unpleasant dreams), nausea and vomiting, increased salivation (hypersalivation), visual disturbances, dizziness and motor restlessness. In addition, ketamine is the only narcotic that increases blood pressure and heart rate. In the context of emergency medicine, it is the only drug that can be used to combine circulatory stabilizing and narcotic effects. Use in patients with severe coronary heart disease (e.g. heart attack) should be avoided because the drug increases the work of the heart by increasing the heart rate and blood pressure and thus increases the oxygen consumption of the heart muscle.
Long-term abuse of ketamine as an intoxicant can damage the urinary tract. Urological complaints (LUTS) and cystitis with the formation of ulcers (ulcerative cystitis) can occur.
In the context of low-dose intravenous use as an antidepressant, ketamine is generally well tolerated.
Caution is advised when administering ketamine and methylphenidate at the same time, as the simultaneous administration of both substances can lead to unpredictable and possibly dangerous interactions.
In Germany, Switzerland and Austria, ketamine requires a prescription, but is not subject to the Narcotics Act or the Austrian Narcotics Act.
Film & television
- Wolfson, Phil .: The Ketamine Papers. ISBN: 0998276502.
More interesting articles
- ↑ https: //clinicaltrials.gov/ct2/show/NCT00088699
- ↑ https: //clinicaltrials.gov/ct2/show/NCT00088699
- ↑ http: //www.beatrice-wagner.de/uploads/media/Artikel_m22.pdf
- ↑ http: //www.welt.de/gesundheit/psychologie/article125641894/Ketamin-ist-die-neue-Hoffnung-fuer-Depressive.html
- ↑ Scheidegger M, Walter M, Lehmann M, Metzger C, Grimm S, Boeker H, Boesiger P, Henning A, Seifritz E. Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PLoS One. 2012; 7 (9): e44799. doi: 10.1371 / journal.pone.0044799. Epub 2012 Sep 24.
- ↑ C. M. Coyle, K. R. Laws: The use of ketamine as an antidepressant: a systematic review and meta-analysis. In: Human psychopharmacology. Volume 30, Number 3, May 2015, pp. 152-163
- ↑ http: //jop.sagepub.com/content/27/5/444.abstract
- ↑ http: //www.ncbi.nlm.nih.gov/pubmed/24740528
- ↑ https: //clinicaltrials.gov/ct2/show/NCT02593643? Term = ketamine + depression & rank = 2
- ↑ https: //clinicaltrials.gov/ct2/show/NCT01887990? Term = ketamine + depression & no_unk = Y & rank = 49
- ↑ Hevers W, Hadley SH, Lüddens H, Amin J: Ketamine, but not phencyclidine, selectively modulates cerebellar GABA (A) receptors containing alpha6 and delta subunits. In: J. Neurosci .. 28, No. 20, 2008, pp. 5383-5393
- ↑ http: //www.webmd.com/depression/news/20140923/ketamine-depression
- ↑ https: //dx.doi.org/10.1017%2FS1461145713000485
- ↑ A. C. Nugent, N. Diazgranados, P. J. Carlson, L. Ibrahim, D. A. Luckenbaugh, N. Brutsche, P. Herscovitch, W. C. Drevets, C. A. Zarate: Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. In: Bipolar disorders. Volume 16, Number 2, March 2014, pp. 119–128
- ↑ https: //bbrfoundation.org/brain-matters-discoveries/2006-breakthrough-rapid-acting-antidepressant-heralded-as-biggest
- ↑ https: //clinicaltrials.gov/show/NCT01998958
- ↑ https: //clinicaltrials.gov/show/NCT01680172
- ↑ https: //clinicaltrials.gov/show/NCT01627782
- ↑ https: //clinicaltrials.gov/show/NCT00088699
- ↑ cf. http://www.aerztezeitung.de/medizin/krankheiten/neuro-psychiatrische_krankheiten/depressionen/article/858662/depression-neue-ansaetze-therapie.html
- ↑ S. Middela, I. Pearce: Ketamine-induced vesicopathy: a literature review. In: International journal of clinical practice Volume 65, number 1, January 2011, pp. 27-30
- ↑ R. Hoffman et al .: Ketamine poisoning. UpToDate 19.1, January 2011.
- ↑ http: //www.ncbi.nlm.nih.gov/pubmed/9041578
- ↑ https: //goo.gl/hHe2ef
- Why is God infinite
- How do I make a gin martini
- How are instruments sterilized?
- What makes a gimmick a gimmick
- Is it worth going into private equity
- What is the purpose of starter shingles
- What is special about Juhi Chawla
- Why is evolution the religion of atheists
- Who would win Wolverine or Beerus?
- How can I make kohl
- What was your most embarrassing upskirt moment
- What is a city jail
- What is the life support system of the earth
- Did any redheads win Miss USA?
- Indeed, neighborhood guards stop any crime
- Is gluten bad for weight training bodybuilding
- Has Russia disconnected RuNet from the Internet
- How can companies compete without lowering prices?
- Is Saenger Udit Narayan Indian or Nepali
- How can you reduce ill-adjusted daydreaming?
- Is humility synonymous with mediocrity
- What do freshmen mean for an organization
- Why does the salt intake wake me up?
- Are TC tornadoes weaker than medium latitude tornadoes
- How do I repair my own windshield?
- Why do earthquakes occur in certain countries
- Why was Thomas Jefferson against John Adams
- Michael Jordan flopped a lot
- How accurate is Life Alert
- Why are plants excreted
- Are parents allowed in the JIPMER Hotel
- Who are the state-sponsored companies
- Why can't Elf talk so well?
- What does Nyaka mean in Bengali